238 related articles for article (PubMed ID: 32889679)
1. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.
Johnson B; Kopetz S
Target Oncol; 2020 Oct; 15(5):567-577. PubMed ID: 32889679
[TBL] [Abstract][Full Text] [Related]
2. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.
Lee HM; Morris V; Napolitano S; Kopetz S
Oncology (Williston Park); 2019 Jun; 33(6):206-11. PubMed ID: 31219603
[TBL] [Abstract][Full Text] [Related]
3. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A; Fakih M; Tabernero J
Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
[TBL] [Abstract][Full Text] [Related]
4. Impact of Metastasectomy in the Multimodality Approach for
Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
[TBL] [Abstract][Full Text] [Related]
5. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future.
Djanani A; Eller S; Öfner D; Troppmair J; Maglione M
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256240
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
7. Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer.
Rodriquenz MG; Ciardiello D; Latiano TP; Maiorano BA; Martinelli E; Silvestris N; Ciardiello F; Maiello E
Crit Rev Oncol Hematol; 2022 May; 173():103657. PubMed ID: 35337969
[TBL] [Abstract][Full Text] [Related]
8. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
[TBL] [Abstract][Full Text] [Related]
9.
Ciombor KK; Strickler JH; Bekaii-Saab TS; Yaeger R
J Clin Oncol; 2022 Aug; 40(24):2706-2715. PubMed ID: 35649231
[No Abstract] [Full Text] [Related]
10. European expert panel consensus on the clinical management of BRAF
Martinelli E; Arnold D; Cervantes A; Stintzing S; Van Cutsem E; Tabernero J; Taieb J; Wasan H; Ciardiello F
Cancer Treat Rev; 2023 Apr; 115():102541. PubMed ID: 36931147
[TBL] [Abstract][Full Text] [Related]
11. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Treatment Landscape in
Tabernero J; Ros J; Élez E
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983
[TBL] [Abstract][Full Text] [Related]
13. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
[TBL] [Abstract][Full Text] [Related]
14. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
Shahjehan F; Kamatham S; Chandrasekharan C; Kasi PM
Drugs Today (Barc); 2019 Nov; 55(11):683-693. PubMed ID: 31840683
[TBL] [Abstract][Full Text] [Related]
15. Treatment of
Ros J; Rodríguez-Castells M; Saoudi N; Baraibar I; Salva F; Tabernero J; Élez E
Expert Rev Anticancer Ther; 2023; 23(8):797-806. PubMed ID: 37482749
[TBL] [Abstract][Full Text] [Related]
16. Treatment options in BRAF-mutant metastatic colorectal cancer.
Bernabe-Ramirez C; Patel R; Chahal J; Saif MW
Anticancer Drugs; 2020 Jul; 31(6):545-557. PubMed ID: 32304411
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of
de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
[TBL] [Abstract][Full Text] [Related]
18. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
Strickler JH; Wu C; Bekaii-Saab T
Cancer Treat Rev; 2017 Nov; 60():109-119. PubMed ID: 28946014
[TBL] [Abstract][Full Text] [Related]
19. Combined BRAF, EGFR, and MEK Inhibition in Patients with
Corcoran RB; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Middleton G; Muro K; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; Humblet Y; De Vos F; Jung AS; Brase JC; Jaeger S; Bettinger S; Mookerjee B; Rangwala F; Van Cutsem E
Cancer Discov; 2018 Apr; 8(4):428-443. PubMed ID: 29431699
[TBL] [Abstract][Full Text] [Related]
20. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.
Tie J; Desai J
Target Oncol; 2015 Jun; 10(2):179-88. PubMed ID: 25119972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
